These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26232690)

  • 1. Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection.
    Liu NW; Cary C; Strine AC; Beck SD; Masterson TA; Bihrle R; Foster RS
    Urology; 2015 Nov; 86(5):981-4. PubMed ID: 26232690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
    Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
    Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
    Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
    Williams SB; Kacker R; Steele GS; Richie JP
    Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
    Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
    Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
    Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
    Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
    Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
    J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer.
    Albqami N; Janetschek G
    J Endourol; 2005; 19(6):683-92; discussion 692. PubMed ID: 16053357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience.
    Steiner H; Peschel R; Janetschek G; Höltl L; Berger AP; Bartsch G; Hobisch A
    Urology; 2004 Mar; 63(3):550-5. PubMed ID: 15028456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
    Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
    Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.